Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

SLNO

Soleno Therapeutics Inc

Sep 15 • 04:00PM ET

51.17

-2.45 -4.57 %

Healthcare • Biotechnology • USA • NASD

Peers: VKTX RZLT MDGL LGND KURA ARDX ASRT ENTA PDSB BTAI

| Held by: VTI IWM XBI VXF IWO VTWO VHT SCHA DWAS VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.15	Insider Own	13.40%	Shs Outstand	50.44M	Perf Week	-29.23%
Market Cap	2.72B	Forward P/E	17.04	EPS next Y	3.00	Insider Trans	-29.28%	Shs Float	46.02M	Perf Month	-33.85%
Enterprise Value	2.49B	PEG	-	EPS next Q	0.04	Inst Own	96.49%	Short Float	16.48%	Perf Quarter	-35.35%
Income	-181.08M	P/S	83.27	EPS this Y	83.98%	Inst Trans	14.00%	Short Ratio	4.83	Perf Half Y	3.71%
Sales	32.66M	P/B	10.75	EPS next Y	527.98%	ROA	-56.90%	Short Interest	7.58M	Perf YTD	13.84%
Book/sh	4.76	P/C	9.48	EPS next 5Y	-	ROE	-69.53%	52W High	90.32 -43.35%	Perf Year	5.33%
Cash/sh	5.40	P/FCF	-	EPS past 3/5Y	9.02% 20.19%	ROIC	-61.96%	52W Low	41.50 23.30%	Perf 3Y	2247.25%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.25%	Volatility	13.88% 6.78%	Perf 5Y	66.41%
Dividend TTM	-	EV/Sales	76.11	EPS Y/Y TTM	-70.28%	Oper. Margin	-570.55%	ATR (14)	4.42	Perf 10Y	-66.22%
Dividend Ex-Date	-	Quick Ratio	15.01	Sales Y/Y TTM	-	Profit Margin	-554.49%	RSI (14)	23.27	Recom	1.09
Dividend Gr. 3/5Y	- -	Current Ratio	15.13	EPS Q/Q	83.51%	SMA20	-22.45%	Beta	-2.76	Target Price	118.73
Payout	-	Debt/Eq	0.22	Sales Q/Q	-	SMA50	-33.30%	Rel Volume	1.45	Prev Close	53.62
Employees	92	LT Debt/Eq	0.22	Earnings	Aug 06 AMC	SMA200	-20.46%	Avg Volume	1.57M	Price	51.17
IPO	Nov 13, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	80.15% 29.92%	Trades		Volume	2,281,867	Change	-4.57%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Initiated	Wells Fargo	Overweight	$123
Jun-23-25	Initiated	TD Cowen	Buy	$110
Mar-05-25	Resumed	Stifel	Buy	$74
Dec-02-24	Reiterated	Stifel	Buy	$74
Dec-02-24	Reiterated	Robert W. Baird	Outperform	$72
Sep-03-24	Initiated	H.C. Wainwright	Buy	$70
May-10-24	Initiated	Robert W. Baird	Outperform	$72
Feb-05-24	Initiated	Piper Sandler	Overweight	$93
Jan-23-24	Initiated	Stifel	Buy	$63
Nov-21-23	Resumed	Guggenheim	Buy	$40
Sep-29-20	Initiated	Guggenheim	Buy	$8
Jan-10-20	Initiated	Craig Hallum	Buy	$8
Dec-23-19	Initiated	Oppenheimer	Outperform	$10
Feb-13-18	Reiterated	Maxim Group	Buy	$8 → $4

Show Previous Ratings

Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive) -5.47%
Sep-11-25 09:35AM	Soleno Therapeutics (SLNO) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.49%
02:18AM	Soleno Therapeutics (SLNO) Falls Hard on Patient Death (Insider Monkey)
Sep-10-25 12:59AM	Here's Why Analysts are Bullish on Soleno Therapeutics (SLNO) (Insider Monkey) -14.52%
Aug-27-25 08:00AM	Soleno Therapeutics to Participate in Upcoming September Conferences (GlobeNewswire)
04:02PM	Loading…
Aug-20-25 04:02PM	Soleno Therapeutics (SLNO) Drops Amid Critical Scorpion Report -- Hagens Berman (PR Newswire)
09:34AM	Nu double upgraded, Novavax downgraded: Wall Street's top analyst calls (The Fly)
Aug-19-25 09:35AM	Down 21.7% in 4 Weeks, Here's Why Soleno Therapeutics (SLNO) Looks Ripe for a Turnaround (Zacks)
Aug-15-25 09:57AM	Soleno Therapeutics stock falls after Scorpion Capital short report (Investing.com) -7.41%
Aug-11-25 09:55AM	How Much Upside is Left in Soleno Therapeutics (SLNO)? Wall Street Analysts Think 43.15% (Zacks)
08:50AM	Here's Why Momentum in Soleno Therapeutics (SLNO) Should Keep going (Zacks)
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 08:00AM	Soleno Therapeutics to Report Second Quarter 2025 Financial Results on August 6, 2025, at 4:30 PM ET (GlobeNewswire)
Jul-25-25 12:00PM	Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy? (Zacks)
09:55AM	Loading…
Jul-23-25 09:55AM	Can Soleno Therapeutics (SLNO) Climb 33.11% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:50AM	Here's What Could Help Soleno Therapeutics (SLNO) Maintain Its Recent Price Strength (Zacks)
Jul-21-25 12:15AM	Soleno Therapeutics' Vykat XR Exceeds Sales Expectations (Insider Monkey)
Jul-10-25 09:59AM	Soleno sales of new Prader-Willi drug rise faster than expected (BioPharma Dive) -9.23%
09:07AM	Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock (GlobeNewswire)
06:01AM	Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock (GlobeNewswire)
06:00AM	Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 (GlobeNewswire)
Jul-01-25 08:00AM	Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025 (GlobeNewswire)
Jun-26-25 03:24PM	TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy (Insider Monkey)
Jun-25-25 08:00AM	Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
Jun-23-25 09:38AM	DoorDash, AMD upgraded: Wall Street's top analyst calls (The Fly)
Jun-20-25 08:00AM	Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference (GlobeNewswire)
May-26-25 09:16AM	EMA validates Solenos application for Prader-Willi syndrome treatment (Pharmaceutical Technology)
May-23-25 05:40PM	Soleno Therapeutics seeking regulatory approval in treatment of PWS (TipRanks)
01:55AM	Soleno Therapeutics, Inc. (SLNO) Secures EMA Validation for PWS Treatment VYKAT XR (Insider Monkey)
05:32PM	Loading…
May-22-25 05:32PM	Soleno Therapeutics Announces Submission and EMA Validation of Marketing Authorization Application for Diazoxide Choline Prolonged-Release Tablets for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome (GlobeNewswire)
May-21-25 08:00AM	Soleno Therapeutics to Participate in Upcoming June Conferences (GlobeNewswire)
May-20-25 04:05PM	Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome (GlobeNewswire)
May-15-25 08:00AM	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025 (GlobeNewswire)
May-13-25 07:00AM	Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 (GlobeNewswire)
May-11-25 05:26PM	Is Soleno Therapeutics (SLNO) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
May-08-25 04:05PM	Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 (GlobeNewswire)
03:30AM	Soleno Therapeutics Inc (SLNO) Q1 2025 Earnings Call Highlights: Navigating Early Success and ... (GuruFocus.com)
May-07-25 10:30PM	Soleno Therapeutics, Inc. (SLNO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
04:01PM	Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-06-25 08:50AM	Soleno Therapeutics (SLNO) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-23-25 02:58PM	TimesSquare U.S. Small Cap Growth Strategy Q1 2025 Commentary (Seeking Alpha)
07:00AM	Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET (GlobeNewswire)
Apr-14-25 07:00AM	Soleno Therapeutics Announces VYKAT(TM) XR Launch (GlobeNewswire)
Mar-29-25 10:39PM	Why Soleno Therapeutics Inc. (SLNO) Went Up Last Week? (Insider Monkey)
Mar-28-25 10:30PM	Why Soleno Therapeutics Inc. (SLNO) Went Up On Friday? (Insider Monkey) +6.83%
04:25AM	Why Soleno Therapeutics Inc. (SLNO) Surged On Thursday? (Insider Monkey)
Mar-27-25 04:18PM	Soleno Surges Into Breakout On Hard-Won Obesity-Tied Approval, But Aardvark Reverses Lower (Investor's Business Daily) +37.61%
04:11PM	Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger (Bloomberg)
03:40PM	Soleno wins FDA approval for Prader-Willi hyperphagia treatment (Pharmaceutical Technology)
02:50PM	Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval (SeekingAlpha)
12:11PM	Soleno stock skyrockets on FDA drug approval (Yahoo Finance Video)
08:46AM	SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug (Zacks)
Mar-26-25 05:15PM	Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome (GlobeNewswire)
01:15PM	First Prader-Willi drug to reduce hunger approved by FDA (BioPharma Dive)
Mar-21-25 09:20AM	Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory (SeekingAlpha)
Feb-27-25 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire) +8.51%
Jan-29-25 04:05PM	Soleno Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-13-25 04:26PM	Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential? (Insider Monkey)
Dec-17-24 04:05PM	Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC (GlobeNewswire)
Nov-27-24 08:00AM	Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
07:40AM	FDA delays decision of Solenos Prader-Willi syndrome drug (Pharmaceutical Technology)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-26-24 10:08AM	Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment (GuruFocus.com)
08:30AM	Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (GlobeNewswire)
Nov-14-24 04:05PM	Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024 (GlobeNewswire)
Nov-06-24 04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-28-24 08:00AM	Soleno Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-25-24 02:44PM	Lamb Weston, Adecoagro, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-21-24 08:00AM	Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D. (GlobeNewswire)
Oct-18-24 06:41PM	TriMas, Soleno Therapeutics, Ring Energy, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-16-24 08:44AM	Soleno Therapeutics (SLNO): Pioneering Treatment for Prader-Willi Syndrome with DCCR (Insider Monkey)
Oct-15-24 06:10PM	Soleno Therapeutics (SLNO): Breakthroughs in Prader-Willi Syndrome Treatment (Insider Monkey)
Oct-10-24 07:04PM	Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. (GuruFocus.com) +7.78%
Oct-08-24 06:29PM	Why Soleno Therapeutics Stock Blasted 9% Higher Today (Motley Fool) +9.11%
08:30AM	Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome (GlobeNewswire)
Oct-03-24 01:03PM	Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc (GuruFocus.com)
Sep-16-24 04:05PM	Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-12-24 01:34AM	Carlyle Group Inc.'s Strategic Reduction in Soleno Therapeutics Inc. (GuruFocus.com)
Aug-28-24 10:13AM	Soleno wins FDA priority review for Prader-Willi therapy (Pharmaceutical Technology)
Aug-27-24 08:51PM	Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer's Top Stock Picks For the Next 12 Months (Insider Monkey) +6.31%
08:00AM	Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (GlobeNewswire)
Aug-19-24 04:17PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.72%
Aug-15-24 08:00AM	Soleno Therapeutics Announces Updates to its Board of Directors (GlobeNewswire)
Aug-07-24 11:53PM	SLNO Stock Earnings: Soleno Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.93%
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-17-24 08:56AM	These Stock Winners Are Strong Buys With More Room Left to Run (TipRanks) -5.57%
Jun-28-24 08:00AM	Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome (GlobeNewswire)
Jun-24-24 05:18PM	Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 08:00AM	Soleno Therapeutics Set to Join Russell 3000 Index (GlobeNewswire)
May-22-24 04:05PM	Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024 (GlobeNewswire)
08:00AM	Soleno Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-15-24 08:00AM	Soleno Therapeutics Stands with the Prader-Willi Syndrome Community (GlobeNewswire)
02:22AM	15 Stocks That Will 10x in 5 Years According to the Analysts (Insider Monkey)
May-10-24 07:16AM	Baird Starts Soleno Therapeutics With Outperform Rating, $72 Price Target (MT Newswires) -5.56%
May-09-24 11:54PM	SLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-03-24 05:46AM	Soleno Therapeutics Prices $138 Million Stock Offering (MT Newswires) -8.35%
May-02-24 10:32PM	Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock (GlobeNewswire)
04:01PM	Soleno Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Abingworth Bioventures VII LP	Shareholder	Aug 11 '25	Proposed Sale	82.15	1,347,522	110,696,581		Aug 15 09:00 PM
Hirano Patricia C	SEE REMARKS	Jul 01 '25	Sale	82.76	3,830	316,971	13,206	Jul 03 04:41 PM
PATRICIA HIRANO	Officer	Jul 01 '25	Proposed Sale	82.76	3,830	316,971		Jul 01 04:03 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Option Exercise	44.25	266	11,770	17,302	Jun 26 06:04 PM
Hirano Patricia C	SEE REMARKS	Jun 24 '25	Sale	84.25	266	22,410	17,036	Jun 26 06:04 PM
PATRICIA HIRANO	Officer	Jun 24 '25	Proposed Sale	84.25	266	22,410		Jun 24 04:07 PM
Hirano Patricia C	SEE REMARKS	Apr 01 '25	Sale	70.11	3,782	265,156	27,036	Apr 02 05:38 PM
PATRICIA HIRANO	Officer	Apr 01 '25	Proposed Sale	70.11	3,782	265,156		Apr 01 04:16 PM
Pauls Matthew	Director	Mar 28 '25	Option Exercise	4.60	5,937	27,310	12,437	Mar 31 07:24 PM
Pauls Matthew	Director	Mar 28 '25	Sale	71.55	5,937	424,797	6,500	Mar 31 07:24 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Option Exercise	4.97	40,638	201,966	101,774	Mar 31 07:23 PM
Yen Kristen	SEE REMARKS	Mar 27 '25	Sale	66.77	95,500	6,376,789	28,143	Mar 31 07:23 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Option Exercise	46.31	37,000	1,713,470	82,351	Mar 31 07:21 PM
Manning Meredith	Chief Commercial Officer	Mar 27 '25	Sale	67.28	45,249	3,044,343	45,351	Mar 31 07:21 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Option Exercise	11.72	70,000	820,125	175,176	Mar 31 07:20 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Mar 27 '25	Sale	69.44	90,622	6,293,177	105,176	Mar 31 07:20 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Option Exercise	21.93	10,000	219,300	46,817	Mar 31 07:18 PM
Huang Michael F.	Sr. VP of Clinical Development	Mar 27 '25	Sale	69.51	14,583	1,013,627	36,817	Mar 31 07:18 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Option Exercise	7.19	72,140	518,557	166,913	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Option Exercise	33.60	2,691	90,418	58,480	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 27 '25	Sale	68.32	128,653	8,789,717	55,789	Mar 31 07:01 PM
Hirano Patricia C	SEE REMARKS	Mar 28 '25	Sale	69.40	27,662	1,919,636	30,818	Mar 31 07:01 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Option Exercise	12.17	523,809	6,373,861	1,100,885	Mar 31 07:00 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Mar 27 '25	Sale	67.62	699,095	47,271,960	577,076	Mar 31 07:00 PM
Vivo Opportunity, LLC	10% Owner	Mar 27 '25	Sale	67.80	1,100,000	74,580,000	4,791,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 26 '25	Sale	65.80	400,000	26,320,000	5,891,851	Mar 28 07:03 PM
Vivo Opportunity, LLC	10% Owner	Mar 28 '25	Sale	70.60	333,557	23,549,124	4,458,294	Mar 28 07:03 PM
PATRICIA HIRANO	Officer	Mar 28 '25	Proposed Sale	69.40	27,662	1,919,636		Mar 28 04:09 PM
Matthew Pauls	Officer	Mar 28 '25	Proposed Sale	67.39	5,937	400,094		Mar 28 12:45 PM
PATRICIA HIRANO	Officer	Mar 27 '25	Proposed Sale	68.31	111,124	7,591,418		Mar 27 04:15 PM
Kristen Yen	Officer	Mar 27 '25	Proposed Sale	50.05	97,006	4,855,150		Mar 27 08:57 AM
Meredith Manning	Officer	Mar 27 '25	Proposed Sale	50.05	48,000	2,402,400		Mar 27 08:56 AM
James H Mackaness	Officer	Mar 27 '25	Proposed Sale	50.05	92,500	4,629,625		Mar 27 08:55 AM
Michael F. Huang	Officer	Mar 27 '25	Proposed Sale	50.05	29,625	1,482,731		Mar 27 08:55 AM
Patricia C Hirano	Officer	Mar 27 '25	Proposed Sale	50.05	23,375	1,169,919		Mar 27 08:54 AM
Bhatnagar Anish	Officer	Mar 27 '25	Proposed Sale	50.05	746,041	37,339,352		Mar 27 08:53 AM
Yen Kristen	SEE REMARKS	Jan 02 '25	Sale	45.41	2,520	114,431	78,945	Jan 06 09:57 PM
Yen Kristen	SEE REMARKS	Jan 03 '25	Sale	46.18	2,340	108,053	76,605	Jan 06 09:57 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Jan 02 '25	Sale	45.41	4,083	185,406	115,089	Jan 06 09:56 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Jan 03 '25	Sale	46.18	3,791	175,055	111,298	Jan 06 09:56 PM
Hirano Patricia C	SEE REMARKS	Jan 02 '25	Sale	45.41	1,571	71,338	107,361	Jan 06 09:56 PM
Hirano Patricia C	SEE REMARKS	Jan 03 '25	Sale	46.18	1,459	67,371	105,902	Jan 06 09:56 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jan 02 '25	Sale	45.41	10,937	496,640	708,616	Jan 06 09:55 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Jan 03 '25	Sale	46.18	10,154	468,875	698,462	Jan 06 09:55 PM
Abingworth Bioventures VII LP	Rule 144 Affiliate	Oct 21 '24	Proposed Sale	54.16	949,336	51,416,038		Oct 21 04:30 PM
Abingworth Bioventures VII LP	Rule 144 Affiliate	Oct 07 '24	Proposed Sale	49.63	2,522,751	125,204,132		Oct 07 04:30 PM
Yen Kristen	SEE REMARKS	Oct 01 '24	Sale	49.43	3,108	153,627	81,465	Oct 03 06:03 PM
Mackaness James H	CHIEF FINANCIAL OFFICER	Oct 01 '24	Sale	49.43	8,077	399,241	119,172	Oct 03 06:02 PM
Hirano Patricia C	SEE REMARKS	Oct 01 '24	Sale	49.43	3,108	153,627	108,932	Oct 03 05:55 PM
Anish Bhatnagar	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Sale	49.43	21,633	1,069,306	719,553	Oct 03 05:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLNO

Soleno Therapeutics Inc

Upgrade your FINVIZ experience